STXS also reported that the Ministry of Health, Labor and Welfare in Japan has classified its Niobe(R) Magnetic Navigation System as a C2 medical device, which recognizes the Niobe system as a new, distinctive technology with clinical benefits and is the highest of five reimbursement categories for medical devices in Japan.
STXS stock closed at $5.06, representing an increase of $1.49 or 41.74%, with a volume of 19,131,266 shares on Wednesday's trading session
STXS is a healthcare technology and innovation leader in the development of robotic cardiology instrument navigation systems designed to enhance the treatment of arrhythmias and coronary disease, as well as information management solutions for the interventional lab.
More about Stereotaxis, Inc. (Nasdaq:STXS) at www.stereotaxis.com
***Crown Equity Holdings Inc. (CRWE) recently reported that, looking to deliver value for its stockholders in both the near and long term, it is refocusing its strategic plan for future growth and services with its original online business-to-business (B2B) marketplace platform for manufacturers and small to large businesses on a global basis to sell and acquire various types of merchandise, targeting the multi-billion dollar B2B Industry with its iB2B Global project.
Strategic plans are also being developed for CRWE’s online video-sharing project to improve the potential future growth for the company, targeting this multi-billion dollar market with its Division CRWETube (www.crwetube.com)
Together with its digital network of websites, CRWE offers advertising branding and marketing services as a worldwide online multi-media publisher.
More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com.
***Immunomedics, Inc. (Nasdaq:IMMU) shares surged after the company reported the issuance of U.S. patent no. 8,562,988 to its majority-owned subsidiary, IBC Pharmaceuticals, Inc., for “Novel Strategies for Improved Cancer Vaccines”, protecting a new vaccine technology targeting dendritic cells for blood cancer treatment.
IMMU last trade was at $4.59, up $0.50 or 12.22%, and a total of 3,561,566 shares exchanged hands during the day
IMMU is a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases.
More about Immunomedics, Inc. (Nasdaq:IMMU) at www.immunomedics.com.
Read Full Disclaimer at http://drstockpick.com/disclaimer